A thymic peptide defined more than forty years ago
Thymosin alpha-1 (Tα1; INN thymalfasin) is a 28-amino-acid peptide identical to the N-terminal fragment of the larger thymic protein prothymosin alpha. It was first isolated from thymus tissue and characterised in the 1970s, and the synthetic form used in clinical and laboratory work is chemically identical to the endogenous peptide. In research settings it is supplied as a lyophilised powder.
It should not be confused with thymosin beta-4, a different peptide and the parent of the fragment sold as TB-500. The two share a name drawn from the thymic fraction they were originally isolated from, not a sequence and not a biology.
What the research describes
Tα1 is an immunomodulatory peptide. The mechanistic literature describes effects on dendritic-cell maturation and T-cell polarisation, with toll-like receptor signalling implicated in preclinical work. Much of that mechanistic literature is preclinical, and that is stated here rather than implied.
The clinical record is deep for the indications where the peptide has been studied. A comprehensive review of the literature surveys trials across chronic hepatitis B and chronic hepatitis C, immune deficiency, oncology and vaccine adjuvancy. The largest single body of evidence concerns chronic hepatitis B, the indication underlying most of its international marketing authorisations. For chronic hepatitis C, the same review records that Tα1 as a monotherapy was not shown to be useful, while combination regimens with pegylated interferon were reported in meta-analysis to outperform interferon alone.
A later pilot trial examined thymalfasin in hospitalised patients with hypoxaemia and lymphocytopenia during the COVID-19 pandemic and reported outcomes in that small population. A pilot trial is not a confirmatory efficacy trial, and it is described here as such.
What the record does not support is the popular framing of Tα1 as a general 'immune booster' for healthy adults. The review literature is explicit that evidence for 'immune optimisation' in healthy people is not established. It is an immunomodulator studied in defined clinical populations, not a wellness supplement.
What trials report on tolerability
The clinical literature describes thymalfasin as generally well tolerated. The adverse effects most often reported are local reactions at the administration site. Where it was used alongside interferon, trials reported rare systemic effects including fever, fatigue, myalgia, nausea and neutropenia compared with interferon alone or placebo. Hypersensitivity to the peptide or its excipients is a stated contraindication, and because of its immunomodulatory action it is treated with caution in immunosuppressed patients, including transplant recipients.
In the UK, adverse effects of medicines are reported through the MHRA Yellow Card scheme. Nothing in this section is a statement of the peptide's safety outside a clinical trial; it is a summary of what published trials report.
Where it sits in UK law
Thymosin alpha-1 holds no UK marketing authorisation and does not appear in the MHRA Products register as a licensed medicine. It is approved under the brand name Zadaxin in more than 35 countries, principally for chronic hepatitis B, but a count of approving countries is not a regulatory verdict: the MHRA, the European Medicines Agency and the US Food and Drug Administration are all absent from that list.
In the UK, a product containing thymosin alpha-1 offered for human use with a medicinal claim is an unlicensed medicine. Its supply engages the Medicines Act 1968 and the Human Medicines Regulations 2012, and the MHRA enforces both against unlicensed supply and against medicinal claims made for material labelled for research. Research-use-only material sits outside that framework only so long as it is genuinely confined to laboratory work — the label is not a route to human use.
The US position, for contrast
The United States has never approved thymosin alpha-1. Its compounding status has moved rather than settled: a 503A bulk-substance nomination was withdrawn by the nominator, and in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding the substance to the 503A bulks list — a non-binding recommendation, not a final rule. It is cited here as a jurisdictional contrast, not as UK law.
What the record supports, and what it does not
Thymosin alpha-1 is one of the few peptides in the research-sector lexicon with a genuine international marketing authorisation and a randomised evidence base behind it. That is the exception in this field, and it is the story. The same record draws the boundary: the evidence supports specific clinical indications in defined populations, not general immune enhancement. In the UK it is unlicensed, and research use only is the only reading consistent with that status.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.